NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions

Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube CarcinomaMetastatic Malignant Female Reproductive System NeoplasmMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaPeritoneal CarcinomatosisPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Malignant Female Reproductive System NeoplasmPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Malignant Female Reproductive System NeoplasmPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Cervical CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IVA Fallopian Tube Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Primary Peritoneal Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8

Interventions

BIOLOGICAL

Ipilimumab

Given i.p.

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given i.p.

OTHER

Pharmacokinetic Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER